KDR and neoplasm: As mentioned above, targeting the VEGF/VEGFR2 axis could lead to hypoxia due to the excessive pruning of the tumor vasculature that may reduce the delivery of anti-cancer agents, affecting altogether to the efficacy of the treatment.